Alpha Tau Medical Ltd (DRTS) Quote

Prof. Aron Popovtzer is leading a study evaluating the synergy between Alpha DaRT and pembrolizumab in patients with inoperable head and neck cancer at Hadassah Medical Center in Jerusalem

https://www.alphatau.com/single-post/combining-alpha-dart-and-immunotherapy-early-results-and-clinical-promisean-interview-with-prof-a/

Promo video with some good history--DD

https://www.alphatau.com/single-post/alpha-tau-to-present-at-jefferies-global-healthcare-conference

CORP UPDATE

https://www.alphatau.com/single-post/alpha-tau-announces-first-quarter-2025-financial-results-and-provides-corporate-update

Dr Den (CMO) interview --https://www.medscape.com/viewarticle/what-not-say-patients-serious-illnesses-2025a1000agp?form=fpf
Dr. Robert Den, Chief Medical Officer at Alpha Tau Medical, was recently featured in Medscape in an article on the importance of language and empathy when speaking to patients facing serious illnesses.

Our intratumoral Radium-224 therapy was developed to address an urgent unmet need: a targeted radiotherapeutic which is designed to deliver potent alpha particles directly into tumors, with the goal of maximizing impact and minimizing systemic burden.

🧭 Next week, we’ll be sharing this approach at two major international conferences:
🔹 ESTRO 2025 in Vienna - advancing the science of precision radiotherapeutics
🔹 DDW 2025 in San Diego - highlighting the growing role of endoscopists in pancreatic cancer care

https://www.alphatau.com/single-post/alpha-tau-announces-closing-of-36-9-million-registered-direct-offering-and-strategic-marketing-alli

Pancreatic Cancer update

Some coverage of the glioblastoma (GBM) study

https://www.clinicaltrialvanguard.com/news/alpha-tau-fda-clearance-for-recurrent-glioblastoma-trial/

https://www.curetoday.com/view/fda-approves-initiation-of-a-new-trial-in-recurrent-glioblastoma

https://www.targetedonc.com/view/fda-approves-ide-application-for-alpha-dart-in-recurrent-glioblastoma

Best believe I'm taking notes!! Lol 😂

Radiation therapies are also evolving. Image-guided superficial radiation therapy is presented as a precise alternative for non-surgical candidates, though Sarnoff expressed uncertainty about its overall effectiveness due to the high number of required sessions. A newer radiation method, Alpha-DART (Diffusing Alpha Emitters Radiation Therapy), involving ultra-thin needles with radioactive seeds, has demonstrated promising preliminary results for recurrent squamous cell carcinoma and has received breakthrough device designation by the FDA.

From here: https://www.managedhealthcareexecutive.com/view/melanoma-treatment-advances-now-crossing-into-other-skin-cancers

MAR 2025 CORP PRESENTATION (PDF file)

https://www.alphatau.com/_files/ugd/74925d_9a8822d204b94bc6810962339ed76366.pdf

FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology

https://www.alphatau.com/single-post/alpha-tau-receives-fda-approval-to-initiate-a-trial-for-patients-with-recurrent-glioblastoma

Presentation at Sidoti small cap

Full year 2024 results--
https://www.morningstar.com/news/globe-newswire/9393383/alpha-tau-announces-full-year-2024-financial-results-and-provides-corporate-update

Read AGAIN-- the previous update on pancreatic cancer patients that have been treated with AlphaDart system
for the first eight patients recruited in a combination trial of Alpha DaRT with pembrolizumab (Keytruda), a checkpoint inhibitor, in treating patients with recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC). A reported systemic objective response rate of 75% and complete response rate of 37.5% were observed, compared to historical benchmarks of 19% and 5%, respectively, for pembrolizumab on its own in the KEYNOTE-048 trial.

Objective Response Rate (ORR):
This is a measure of treatment efficacy, calculated as the percentage of patients who achieve a complete response (CR) or a partial response (PR) to treatment.
Complete Response (CR): No evidence of the disease is detected.

Update pancreas cancer results

high volume today

institutional own 1.40%

take a seat gentlemen

thank you for sharing that

🙊 AlphaTau will be presenting @ 3 conferences in MAR

https://www.alphatau.com/single-post/alpha-tau-to-participate-in-march-investor-conferences

havent checked in in a long time. Glad to be back
What happened here? All in shambles

Pancreatic cancer--FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT

https://www.globenewswire.com/news-release/2025/02/03/3019526/0/en/Alpha-Tau-Announces-FDA-Approval-of-IDE-Supplement-to-Expand-Pilot-Trial-of-Alpha-DaRT-to-Thirty-Patients-with-Pancreatic-Cancer-in-Two-Cohorts-with-Locally-Advanced-or-Metastatic-.html

Timber.........

Webcast archive from todays update

https://alpha-tau-medical-2025-rd-day.open-exchange.net/webcast

Its relevant for people that are new to the board. Always look at how they started.
cliffnotes. Keep in mind the company is based in Jerusalem.

- The transaction represents an implied pro forma equity value of approximately $1 billion and is expected to provide up to $367 million in gross proceeds, including up to $275 million of cash held in the trust account of Healthcare Capital Corp. (Nasdaq: HCCC) and a $92 million PIPE.

- Citigroup is acting as financial advisor to Alpha Tau. Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE. Cantor Fitzgerald is acting as a capital markets advisor to HCC. Value Base M&A Ltd. is also acting as financial advisor on the transaction.

Latham & Watkins LLP and Meitar | Law Offices are acting as legal advisors to Alpha Tau. Ellenoff Grossman & Schole LLP and FBC & Co. are acting as legal advisors to HCC. Winston & Strawn LLP is acting as legal advisor to the placement agents.

You posted the same link 1 month ago.

Also that article/link is 3 1/2 years old

coming to life
https://www.alphatau.com/single-post/alpha-tau-healthcare-capital-corp-to-combine-and-create-a-1-billion-publicly-traded-company

DRTS GOOD BIOS WITH A STRONG PIPELINE WILL DO OKAY IN 2025...SPEC BIOS WILL GET WIPED OUT!

DRTS BREAKING 4 BUCKS ON ITS WAY TO 4.59 TARGET...WEEKLY BREAK OUT

👇 This is what happens when you show up after the stock moves!! Headed back to 2's then maybe back up!!

Now you want to be the Riddler?? Lol!! I'm busy mastering my universe!!

You can get did you put over 10K worth of confidence in it!!

Can I get part of that "no post before JAN" bet ??

WHEN WE ARE OUT OF THIS MARKET CHOP...DO YOU KNOW WHAT THE CHOP IS.....GOOGLE IT..YA MIGHT LEARN SOMETHING.

I put it on my watch list!! 4.50 when?? This year, month, week?? I'm on to you!! Another empty prediction!!

WEIRDO...WATCH AND LEARN T0 4.50

I bet you don't have a post before January!! My name is Acme and I approve this message!!

DRTS...ADDING DIPS...FAVO BIO FOR 2025

here it comes

DRTS HERE WE GO

DRTS NEW BIO BEAST AS WEEKLY SETS UP FOR BREAK OUT

Investor update day

https://www.ourcrowd.com/startup-news/alpha-tau-100-complete-response-rate-in-skin-cancer-trial?
might become SOC in inoperable tumors - super tech - revolutionize radio

has a lot of critical readouts coming soon - see below
neglected and forgotten...

https://www.alphatau.com/single-post/alpha-tau-healthcare-capital-corp-to-combine-and-create-a-1-billion-publicly-traded-company

Great Israeli company -- coming to life ahead of a few readouts

3rd QTR update: 2+ years op cash. Trial expansion.
FDA accepted for TAP--Total Product Life Cycle Advisory Program (TAP)
FDA approval of an Investigational Device Exemption (IDE) application for cSCC

https://www.alphatau.com/single-post/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update